ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Q2FY27 revenue ₹316 Cr (+30% YoY), EBITDA ₹68 Cr at 21% margin, PAT ₹40 Cr (+57%). Strategy: backward integration, high-value APIs, DMF/CEP filings, ₹280 Cr capex.
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharma delivered FY26 revenue of ₹887cr (+13%) and PAT of ₹102cr (+47%). Strategy focuses on backward integration and high-margin API expansion.
SMS Pharma reported strong FY26 performance with PAT reaching ₹102 crore (up 48% YoY) and EBITDA margins expanding to 19%.